NEU neuren pharmaceuticals limited

Share Price, page-3582

  1. 2,573 Posts.
    lightbulb Created with Sketch. 2705
    I spoke to Jon Pilcher regarding RSBQ and this is his response:

    Everyone seems to be fixating on the subscales, none of which were an endpoint in the clinical trials. The co-primary endpoint was the Total score. If you read the whole manuscript, the concluding paragraph of the Discussion states "In summary the analyses presented here support the use of the RSBQ in children and adults with RTT". It also states that the Total scale has "good psychometric properties". So the manuscript is actually supportive, not critical. It recommends some reorganisation of the subscales, but that doesn't impact the Total scale. Neither the manuscript nor the E&P report says anything about Acadia submitting or having to submit any new analysis - someone has just made that up.

    As a reminder, at Neuren's End of Phase 2 Meeting with FDA the use of RSBQ Total and CGI-I as co-primary endpoints for the Phase 3 trial was agreed. The elevation of CGI-I to co-primary (a higher bar) was a specific request from FDA in order that a positive CGI-I result would provide corroboration of the clinical meaningfulness of a positive RSBQ result, recognising that RSBQ had not been used in a registration trial before and was not specifically designed for interventional trials.

    Regards, Jon
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$14.60
Change
0.420(2.96%)
Mkt cap ! $1.806B
Open High Low Value Volume
$14.36 $14.75 $14.36 $7.523M 515.8K

Buyers (Bids)

No. Vol. Price($)
7 290 $14.59
 

Sellers (Offers)

Price($) Vol. No.
$14.61 485 6
View Market Depth
Last trade - 14.30pm 10/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.